AIDS is a highly dangerous infectious disease. According to UN statistics, there are 37 million 700 thousand HIV infected people worldwide in 2020. However, up to now, modern medicine still has no way to cure AIDS. Once infected, it will lead to a lifelong illness.
Recently, according to the latest information published by the National Institutes of Health (NIH) clinical trial research, Moderna launched the human clinical trial of HIV vaccine (Moderna) based on mRNA technology platform in local time on August 19th, and is scheduled to be completed in the spring 2023.
Over the years, researchers have been studying the potential of mRNA vaccine. The mRNA based vaccine launched by COVID-19, Pfizer Inc and Moderna has been proved to be widely safe and effective in preventing and reducing the severity of COVID-19 infection. Therefore, people began to expect that the mRNA platform can also prevent other pathogens.
It is understood that the Moderna company's AIDS vaccine human trial cooperation mechanism is University of Texas Sanantonio branch, George Washington University, Fred Hutchinson cancer research center and Emory University, research platform for the company's 2019 coronavirus disease vaccine the same messenger ribonucleic acid platform. To further evaluate the safety and immunogenicity of HIV vaccine.
A total of 56 HIV negative participants aged 18 to 56 were enrolled in the trial, and two candidate vaccines mRNA-1644 and mRNA-1644v2-Core had passed initial safety tests. It is worth mentioning that this is the first human trial of HIV vaccine based on mRNA technology.
If the vaccine passes the phase 1 clinical trial, Moderna will carry out phase II and phase III trials to determine the effect of the vaccine on preventing HIV infection in a wider population. In the future, with the maturity of mRNA vaccine technology, it is expected to accelerate the listing of HIV vaccine as soon as possible.
More information, please pay attention to EVO WeChat official account.